^Baggiolini M, Schnyder J, Bretz U, Dewald B, Ruch W. Cellular mechanisms of proteinase release from inflammatory cells and the degradation of extracellular proteins. Ciba Foundation Symposium. Novartis Foundation Symposia. 1979, (75): 105–21. ISBN 9780470720585. PMID 399884. doi:10.1002/9780470720585.ch7.
^Virca GD, Metz G, Schnebli HP. Similarities between human and rat leukocyte elastase and cathepsin G. European Journal of Biochemistry. October 1984, 144 (1): 1–9. PMID 6566611. doi:10.1111/j.1432-1033.1984.tb08423.x.
^Salvesen G, Enghild JJ. Zymogen activation specificity and genomic structures of human neutrophil elastase and cathepsin G reveal a new branch of the chymotrypsinogen superfamily of serine proteinases. Biomedica Biochimica Acta. 1991, 50 (4–6): 665–71. PMID 1801740.
^Salvesen G, Farley D, Shuman J, Przybyla A, Reilly C, Travis J. Molecular cloning of human cathepsin G: structural similarity to mast cell and cytotoxic T lymphocyte proteinases. Biochemistry. April 1987, 26 (8): 2289–93. PMID 3304423. doi:10.1021/bi00382a032.
^Korkmaz B, Moreau T, Gauthier F. Neutrophil elastase, proteinase 3 and cathepsin G: physicochemical properties, activity and physiopathological functions. Biochimie. February 2008, 90 (2): 227–42. PMID 18021746. doi:10.1016/j.biochi.2007.10.009.
^Shafer WM, Pohl J, Onunka VC, Bangalore N, Travis J. Human lysosomal cathepsin G and granzyme B share a functionally conserved broad spectrum antibacterial peptide. The Journal of Biological Chemistry. January 1991, 266 (1): 112–6. PMID 1985886. doi:10.1016/S0021-9258(18)52409-1.
^Bank U, Ansorge S. More than destructive: neutrophil-derived serine proteases in cytokine bioactivity control. Journal of Leukocyte Biology. February 2001, 69 (2): 197–206. PMID 11272269. S2CID 30791872. doi:10.1189/jlb.69.2.197.
^Reilly CF, Tewksbury DA, Schechter NM, Travis J. Rapid conversion of angiotensin I to angiotensin II by neutrophil and mast cell proteinases. The Journal of Biological Chemistry. August 1982, 257 (15): 8619–22. PMID 6807977. doi:10.1016/S0021-9258(18)34171-1.
^Sambrano GR, Huang W, Faruqi T, Mahrus S, Craik C, Coughlin SR. Cathepsin G activates protease-activated receptor-4 in human platelets. The Journal of Biological Chemistry. March 2000, 275 (10): 6819–23. PMID 10702240. doi:10.1074/jbc.275.10.6819.
^Nadel JA. Role of mast cell and neutrophil proteases in airway secretion. The American Review of Respiratory Disease. September 1991, 144 (3 Pt 2): S48–51. PMID 1892327. doi:10.1164/ajrccm/144.3_pt_2.S48.
^Armao D, Kornfeld M, Estrada EY, Grossetete M, Rosenberg GA. Neutral proteases and disruption of the blood-brain barrier in rat. Brain Research. September 1997, 767 (2): 259–64. PMID 9367256. S2CID 40103486. doi:10.1016/S0006-8993(97)00567-2.
^Kawabata K, Hagio T, Matsuoka S. The role of neutrophil elastase in acute lung injury. European Journal of Pharmacology. September 2002, 451 (1): 1–10. PMID 12223222. doi:10.1016/s0014-2999(02)02182-9.
^Liu X, Tian Y, Meng Z, Chen Y, Ho IH, Choy KW, Lichtner P, Wong SH, Yu J, Gin T, Wu WK, Cheng CH, Chan MT. Up-regulation of Cathepsin G in the Development of Chronic Postsurgical Pain: An Experimental and Clinical Genetic Study. Anesthesiology. October 2015, 123 (4): 838–50. PMID 26270939. S2CID 43571196. doi:10.1097/ALN.0000000000000828.
^Son ED, Shim JH, Choi H, Kim H, Lim KM, Chung JH, Byun SY, Lee TR. Cathepsin G inhibitor prevents ultraviolet B-induced photoaging in hairless mice via inhibition of fibronectin fragmentation. Dermatology. 2012, 224 (4): 352–60. PMID 22759782. S2CID 29489606. doi:10.1159/000339337.
^Cruz-Silva I, Neuhof C, Gozzo AJ, Nunes VA, Hirata IY, Sampaio MU, Figueiredo-Ribeiro Rde C, Neuhof H, Araújo Mda S. Using a Caesalpinia echinata Lam. protease inhibitor as a tool for studying the roles of neutrophil elastase, cathepsin G and proteinase 3 in pulmonary edema. Phytochemistry. December 2013, 96: 235–43. PMID 24140156. doi:10.1016/j.phytochem.2013.09.025.
Shafer WM, Katzif S, Bowers S, Fallon M, Hubalek M, Reed MS, Veprek P, Pohl J. Tailoring an antibacterial peptide of human lysosomal cathepsin G to enhance its broad-spectrum action against antibiotic-resistant bacterial pathogens. Current Pharmaceutical Design. 2002, 8 (9): 695–702. PMID 11945165. doi:10.2174/1381612023395376.
Cohen AB, Stevens MD, Miller EJ, Atkinson MA, Mullenbach G. Generation of the neutrophil-activating peptide-2 by cathepsin G and cathepsin G-treated human platelets. The American Journal of Physiology. August 1992, 263 (2 Pt 1): L249–56. PMID 1387511. doi:10.1152/ajplung.1992.263.2.L249.
Maison CM, Villiers CL, Colomb MG. Proteolysis of C3 on U937 cell plasma membranes. Purification of cathepsin G. Journal of Immunology. August 1991, 147 (3): 921–6. PMID 1861080.
Brandt E, Van Damme J, Flad HD. Neutrophils can generate their activator neutrophil-activating peptide 2 by proteolytic cleavage of platelet-derived connective tissue-activating peptide III. Cytokine. July 1991, 3 (4): 311–21. PMID 1873479. doi:10.1016/1043-4666(91)90499-4.
Kargi HA, Campbell EJ, Kuhn C. Elastase and cathepsin G of human monocytes: heterogeneity and subcellular localization to peroxidase-positive granules. The Journal of Histochemistry and Cytochemistry. August 1990, 38 (8): 1179–86. PMID 2164060. doi:10.1177/38.8.2164060.
Pratt CW, Tobin RB, Church FC. Interaction of heparin cofactor II with neutrophil elastase and cathepsin G. The Journal of Biological Chemistry. April 1990, 265 (11): 6092–7. PMID 2318847. doi:10.1016/S0021-9258(19)39296-8.
Hohn PA, Popescu NC, Hanson RD, Salvesen G, Ley TJ. Genomic organization and chromosomal localization of the human cathepsin G gene. The Journal of Biological Chemistry. August 1989, 264 (23): 13412–9. PMID 2569462. doi:10.1016/S0021-9258(18)80012-6.
Livesey SA, Buescher ES, Krannig GL, Harrison DS, Linner JG, Chiovetti R. Human neutrophil granule heterogeneity: immunolocalization studies using cryofixed, dried and embedded specimens. Scanning Microscopy. Supplement. 1989, 3: 231–9; discussion 239–40. PMID 2616953.
Campbell EJ, Silverman EK, Campbell MA. Elastase and cathepsin G of human monocytes. Quantification of cellular content, release in response to stimuli, and heterogeneity in elastase-mediated proteolytic activity. Journal of Immunology. November 1989, 143 (9): 2961–8. PMID 2681419.
Salvesen G, Farley D, Shuman J, Przybyla A, Reilly C, Travis J. Molecular cloning of human cathepsin G: structural similarity to mast cell and cytotoxic T lymphocyte proteinases. Biochemistry. April 1987, 26 (8): 2289–93. PMID 3304423. doi:10.1021/bi00382a032.
Heck LW, Rostand KS, Hunter FA, Bhown A. Isolation, characterization, and amino-terminal amino acid sequence analysis of human neutrophil cathepsin G from normal donors. Analytical Biochemistry. October 1986, 158 (1): 217–27. PMID 3799965. doi:10.1016/0003-2697(86)90612-3.
Klickstein LB, Kaempfer CE, Wintroub BU. The granulocyte-angiotensin system. Angiotensin I-converting activity of cathepsin G. The Journal of Biological Chemistry. December 1982, 257 (24): 15042–6. PMID 6294088. doi:10.1016/S0021-9258(18)33390-8.
LaRosa CA, Rohrer MJ, Benoit SE, Barnard MR, Michelson AD. Neutrophil cathepsin G modulates the platelet surface expression of the glycoprotein (GP) Ib-IX complex by proteolysis of the von Willebrand factor binding site on GPIb alpha and by a cytoskeletal-mediated redistribution of the remainder of the complex. Blood. July 1994, 84 (1): 158–68. PMID 7517206. doi:10.1182/blood.V84.1.158.158.
Maruyama K, Sugano S. Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides. Gene. January 1994, 138 (1–2): 171–4. PMID 8125298. doi:10.1016/0378-1119(94)90802-8.